Related Experiment Video
Updated: Jun 1, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Hepatocellular carcinoma with sarcomatous change.
Oncology Reports
|May 19, 2011
Summary
Hepatocellular carcinoma (HCC) with sarcomatous change is rare (1.9%). These tumors exhibit distinct immunohistochemical features and high malignant potential, independent of prior therapy.
Area of Science:
- Oncology
- Pathology
Background:
- Hepatocellular carcinoma (HCC) is a primary liver cancer.
- Sarcomatous change in HCC represents a rare but aggressive subtype.
Purpose of the Study:
- To investigate the clinicopathological and immunohistochemical characteristics of HCC with sarcomatous change.
- To evaluate the potential relationship between sarcomatous change and preoperative therapy.
Main Methods:
- Analysis of surgically resected HCC cases.
- Immunohistochemical staining for specific proteins (albumin, alpha 1-antichymotrypsin, alpha-fetoprotein, cytokeratin, vimentin, p53, mouse double minute-2).
- Assessment of proliferating cell nuclear antigen (PCNA) labeling index.
Main Results:
- Sarcomatous change was observed in 1.9% (6/308) of HCC cases.
- Only one case received preoperative therapy, suggesting sarcomatous change is not solely therapy-induced.
- Sarcomatous components were positive for albumin and alpha 1-antichymotrypsin, negative for alpha-fetoprotein.
- Heterogeneous expression of intermediate filament proteins (cytokeratin, vimentin) was noted.
- Elevated p53 and/or mouse double minute-2 protein expression and higher PCNA index indicated high proliferative activity and malignant potential.
Conclusions:
- HCC with sarcomatous change is an uncommon entity with unique immunohistochemical markers.
- These tumors demonstrate aggressive biological behavior characterized by high proliferation and malignant potential.
- Further research is warranted to understand the pathogenesis and optimize treatment strategies for this HCC subtype.
Related Concept Videos
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...